JUL 2·SEC EDGARLow
Han Yusheng purchased $6.2M of BNR
Han Yusheng purchased 731,410 shares of Burning Rock Biotech Ltd (BNR) at an average of $8.45 ($7.45–$9.25, $6.18M total) across 7 trades over 2026-06-11 to 2026-06-26.
StockNASDAQ · US · USDHealthcare · Diagnostics & Research
$BNR
Burning Rock Biotech Ltd
Price · $BNRvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $BNR in the last 7 days.
Insider · 30dAll trades →
No SEC Form 4 filings for $BNR in the last 30 days.
See all $BNR insider activity →Top stories · $BNRMore →
JUL 2·manilatimes.net
Burning Rock Announces Founder’s Purchase of Its ADSs
Burning Rock Biotech Limited (NASDAQ: BNR) said founder/CEO/chairman Yusheng Han bought 73,141 ADSs for $618,217.72 from the open market. The company added that, combined with 72,733 ADSs bought in the last two post-earnings windows, Han has bought 145,874 ADSs for $1,976,542.90 across three windows, subject to insider-trading rules.
JUN 12·benzinga.com
Why These High-Flying Stocks Came Back To Earth - Burning Rock Biotech (NASDAQ:BNR), GameStop (NYSE:GME)
The article says several small- and midcap U.S.-listed Chinese stocks, including Here Group, Zepp Health, Burning Rock Biotech and So-Young International, surged in 2025 but have largely retraced gains in 2026. It links the rally-and-reversal to investor interest in undervaluation and to U.S. scrutiny of suspected stock manipulation. It also notes Nasdaq rules requiring $25m minimum proceeds for new Chinese listings and delisting if value falls below $5m.
BNR sentiment & insider activity
Recent BNR coverage spans financial news, insider activity and sector analysis.
What's driving BNR
Insider open-market buying by a director is a modest bullish signal, but it is not a new fundamental catalyst like earnings or guidance.
This is a fresh insider-buy disclosure that may support near-term sentiment, but it does not change fundamentals or guidance in the text.
Regulatory-driven business model shift (at-home to in-hospital) is the core fundamental swing factor for BNR’s revenue mix and margin trajectory.
Burning Rock Biotech (BNR) reports continued unprofitability despite reduced losses, with steady revenue but persistent net losses. The stock trades at a low price-to-sales ratio, but high volatility and ongoing losses raise concerns about future profitability.
Burning Rock reported its third quarter 2025 financial results, indicating its current financial health and growth trajectory.
alphai scores every news story that mentions BNR with an AI model for sentiment and relevance, and aggregates insider trades from Burning Rock Biotech Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $BNR
Score
Han Yusheng purchased $6.2M of BNR
Han Yusheng purchased 731,410 shares of Burning Rock Biotech Ltd (BNR) at an average of $8.45 ($7.45–$9.25, $6.18M total) across 7 trades over 2026-06-11 to 2026-06-26.
2 min read
Burning Rock Announces Founder’s Purchase of Its ADSs
Burning Rock Biotech Limited (NASDAQ: BNR) said founder/CEO/chairman Yusheng Han bought 73,141 ADSs for $618,217.72 from the open market. The company added that, combined with 72,733 ADSs bought in the last two post-earnings windows, Han has bought 145,874 ADSs for $1,976,542.90 across three windows, subject to insider-trading rules.
2 min read
Why These High-Flying Stocks Came Back To Earth - Burning Rock Biotech (NASDAQ:BNR), GameStop (NYSE:GME)
The article says several small- and midcap U.S.-listed Chinese stocks, including Here Group, Zepp Health, Burning Rock Biotech and So-Young International, surged in 2025 but have largely retraced gains in 2026. It links the rally-and-reversal to investor interest in undervaluation and to U.S. scrutiny of suspected stock manipulation. It also notes Nasdaq rules requiring $25m minimum proceeds for new Chinese listings and delisting if value falls below $5m.
7 min read
Burning Rock Biotech (BNR) Loss Reduction Trend Tests Bearish Profitability Concerns
Burning Rock Biotech (BNR) recently reported its Q3 2025 results, showing a reduction in net losses but persistent unprofitability. Despite steady revenue around C¥130 million quarterly and C¥539.3 million trailing 12-month revenue, the company posted a C¥16.8 million loss in Q3 2025, challenging bullish arguments without clearer margin progress. The stock trades at a lower price-to-sales ratio (3.1x) compared to peers, coupled with high share price volatility, highlighting investor concerns about sustained losses.
3 min readBurning Rock Reports Third Quarter 2025 Financial Results
GUANGZHOU, China, Nov. 20, 2025 ( GLOBE NEWSWIRE ) -- Burning Rock Biotech Limited ( NASDAQ: BNR, the "Company" or "Burning Rock" ) , a company focused on the application of next generation sequencing ( NGS ) technology in the field of precision oncology, today reported financial results for the ...
2 min read
Burning Rock's OncoGuide™ OncoScreen™ Plus CDx System Now Approved in Japan as a Companion Diagnostic for Capivasertib in Breast Cancer - Burning Rock Biotech (NASDAQ:BNR)
TOKYO and GUANGZHOU, China, Sept. 24, 2025 ( GLOBE NEWSWIRE ) -- Riken Genesis Co., Ltd. ( Riken Genesis ) and Burning Rock Biotech Limited BNR "Burning Rock" ) ) today announced that the OncoGuide™ OncoScreen™ Plus CDx System based on OncoScreen™ Plus to be used as a companion diagnostic for ...
3 min read
Burning Rock's OncoGuide™ OncoScreen™ Plus CDx System Now Approved in Japan as a Companion Diagnostic for Capivasertib in Breast Cancer
TOKYO and GUANGZHOU, China, Sept. 24, 2025 ( GLOBE NEWSWIRE ) -- Riken Genesis Co., Ltd. ( Riken Genesis ) and Burning Rock Biotech Limited ( NASDAQ: BNR, "Burning Rock" ) today announced that the OncoGuide™ OncoScreen™ Plus CDx System based on OncoScreen™ Plus to be used as a companion ...
3 min readBurning Rock Reports Second Quarter 2025 Financial Results
GUANGZHOU, China, Sept. 08, 2025 ( GLOBE NEWSWIRE ) -- Burning Rock Biotech Limited ( NASDAQ: BNR, the "Company" or "Burning Rock" ) , a company focused on the application of next generation sequencing ( NGS ) technology in the field of precision oncology, today reported financial results for ...
2 min read